Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Go back to Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
Enliven Marketing Technologies Corporation (NASDAQ: ENLV) Delayed: 4.36 -0.23 (5.01%)
Previous Close $4.59    52 Week High $0.94 
Open $4.52    52 Week Low $0.47 
Day High $4.61    P/E N/A 
Day Low $4.30    EPS $-0.11 
Volume 130,624